HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effect of propionyl-L-carnitine on quality of life in intermittent claudication.

Abstract
A double-blind, dose titration study was designed to assess the efficacy of propionyl-L-carnitine in intermittent claudication. The effect on walking capacity was described in a previous article. This study reports on the effect on quality of life, assessed by the McMaster Health Index Questionnaire (MHIQ). After 24 weeks of treatment, the global MHIQ score did not show any difference from baseline in patients randomized to placebo (n = 102). Conversely, it increased from 0.59 +/- 0.12 to 0.64 +/- 0.12 in those taking propionyl-L-carnitine (n = 85). Analysis of variance showed a significant difference between treatments (p = 0.018). Stepwise multiple regression analysis identified baseline maximal walking capacity (cutoff point 250 m) as a predictor of treatment outcome. In patients walking < 250 m, propionyl-L-carnitine significantly improved physical function (p = 0.027), emotional function (p = 0.002), and global MHIQ score (p = 0.002) compared with placebo. Also, for maximal walking capacity, group difference significantly favored propionyl-L-carnitine (p = 0.009). In patients with baseline maximal walking capacity > or = 250 m, propionyl-L-carnitine did not affect the MHIQ scores, nor improve walking performance. These data indicate that propionyl-L-carnitine exerts beneficial effects on quality of life and walking performance in patients with more severely limited walking capacity.
AuthorsG Brevetti, S Perna, C Sabba, V D Martone, A Di Iorio, G Barletta
JournalThe American journal of cardiology (Am J Cardiol) Vol. 79 Issue 6 Pg. 777-80 (Mar 15 1997) ISSN: 0002-9149 [Print] United States
PMID9070558 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Cardiotonic Agents
  • propionylcarnitine
  • Carnitine
Topics
  • Aged
  • Cardiotonic Agents (therapeutic use)
  • Carnitine (analogs & derivatives, therapeutic use)
  • Double-Blind Method
  • Female
  • Humans
  • Intermittent Claudication (drug therapy, physiopathology)
  • Italy
  • Male
  • Middle Aged
  • Quality of Life
  • Surveys and Questionnaires
  • Time Factors
  • Walking

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: